"Alfentanilum"@en . "For intravenous injection or infusion only. "@en . "* 0.4 to 1 L/kg"@en . " "@en . . . . . . . . "Jacob Mathew, J. Killgore, \"New methods for the synthesis of alfentanil, sufentanil, and remifentanil.\" U.S. Patent US20060149071, issued July 06, 2006."@en . . . . . "Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability."@en . "Only 1.0% of the dose is excreted as unchanged drug; urinary excretion is the major route of elimination of metabolites."@en . . "A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. [PubChem]"@en . "Humans and other mammals"@en . . . . . . . "90-111 minutes"@en . . . "Symptoms of overexposure include characteristic rigidity of the skeletal muscles, cardiac and respiratory depression, and narrowing of the pupils."@en . . . . . . "illicit"@en . "N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide"@en . . . . . . . . . . . . . . . . . "* 5 mL/kg/min"@en . "For the management of postoperative pain and the maintenance of general anesthesia."@en . . . . "Alfentanyl"@en . . . . "92%"@en . . . "Alfentanil"@en . . . "71195-58-9"@en . . "approved"@en . .